A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

Healthy Volunteers Clinical Trial

Official title:

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Single Centre, 3-Part, Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03381144
• Other study ID #: GB40223
• Secondary ID: 2017-003498-33
• Status: Terminated
• Phase: Phase 1
• Start date: December 8, 2017
• Est. completion date: April 29, 2019

Study information

• Verified date: October 2019
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, single-center, three-part study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of single and multiple ascending doses of GDC-0334 and the effect of food on the pharmacokinetics of GDC-0334 in healthy adult participants.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 66
• Est. completion date: April 29, 2019
• Est. primary completion date: April 29, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy males or non-pregnant, non-lactating healthy females. Females may be of non-childbearing potential or childbearing potential. Healthy females of childbearing potential must agree to use a highly effective method of contraception.

• Healthy males must agree to use an adequate method of contraception

• Body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m^2) or, if outside the range, considered not clinically significant by the investigator

• Must be willing and able to communicate and participate in the whole study

Exclusion Criteria:

• Participants who have received any investigational medicinal product in a clinical research study within the previous 3 months

• Participants who are study site employees, or immediate family members of a study site or sponsor employee

• Participants who have previously been enrolled in this study. Participants who have enrolled in Part 1 are not permitted to enrol in Parts 2 or 3, and participants who have enrolled in Part 2 are not permitted to enroll in Part 3

• History of any drug or alcohol abuse in the past 2 years

• Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, 25 milliliters (mL) of 40% spirit or a 125-mL glass of wine)

• Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 6 parts per million (ppm) at screening or admission

• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

• Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

• Clinically significant abnormal biochemistry, hematology or urinalysis as judged by the investigator

• Positive drugs-of-abuse test result at screening or admission

• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) results

• Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <70 milliliters per minute (mL/min) using the Cockcroft-Gault equation

• History of seizure

• History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by the investigator

• Participants with a history of cholecystectomy or gall stones (applies to any regimen where food effect is being explored)

• History of serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

• Presence or history of active allergy requiring treatment, as judged by the investigator. History of hayfever is allowed unless it is active.

• Donation or loss of greater than 400 mL of blood within the previous 3 months

• Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days or 5 half-lives, whichever is longer, before investigational medicinal product administration. Exceptions may apply on a case-by-case basis, if considered not to interfere with the objectives of the study, as agreed by the principal investigator and sponsor's medical monitor.

• History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction, at screening or admission

• QT interval corrected using Fridericia's formula (QTcF) > 450 milliseconds (msec) demonstrated by at least two ECGs >30 minutes apart

• History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome

• Current treatment with medications that are well known to prolong the QT interval

• History of dermatographism

• Presence or history of clinically significant skin disorders, as judged by the investigator (Parts 1 and 3 only)

• History of trauma or surgery (laceration repair is not excluded) to the arm but not including wrist or hand injury/surgery (Parts 1 and 3 only)

• Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• GDC-0334
Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
• Placebo
Participants will receive GDC-0334-matching placebo.

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical Ltd, Clinical Research Unit	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants with Adverse Events		From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)
Primary	Severity of Adverse Events, as Graded per the World Health Organization (WHO) Toxicity Grading Scale		From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)
Primary	Change from Baseline in Blood Pressure		Up to approximately 42 days
Primary	Change from Baseline in Heart Rate		Up to approximately 42 days
Primary	Incidence of Electrocardiogram (ECG) Abnormalities		Up to approximately 42 days
Primary	Incidence of Clinical Laboratory Abnormalities		Up to approximately 30 days
Primary	Incidence of Physical Examination Abnormalities		Up to approximately 42 days
Primary	Incidence of Neurological Examination Abnormalities		Up to approximately 31 days
Primary	Columbia-Suicide Severity Rating Scale (C-SSRS) - Part 3 Only		Up to approximately 42 days
Secondary	Elapsed Time from Dosing at Which GDC-0334 is First Quantifiable in a Concentration versus Time profile (Tlag )		Up to approximately 35 days
Secondary	Time to Maximum Plasma Concentration (Tmax) for GDC-0334		Up to approximately 35 days
Secondary	Maximum Observed Plasma Concentration (Cmax) for GDC-0334		Up to approximately 35 days
Secondary	Concentration at 24 hours Post-dose (C24) for GDC-0334		Up to approximately 35 days
Secondary	Concentration at 12 hours Post-dose (C12) for GDC-0334		Up to approximately 35 days
Secondary	Area Under the Plasma Concentration Curve from Time Zero to the Last Measurable Concentration (AUC0-t) for GDC-0334		Up to approximately 35 days
Secondary	Area Under the Plasma Concentration Curve from Time Zero Extrapolated to Infinity (AUC0-inf) for GDC-0334		Up to approximately 35 days
Secondary	Percentage of AUC0-inf Accounted for by Extrapolation to Infinity (AUC%extrap) for GDC-0334		Up to approximately 35 days
Secondary	Apparent Terminal Elimination Half-Life (t1/2) for GDC-0334		Up to approximately 35 days